Antares Therapeutics is a new Boston-based biotech company, launched in June 2025, that develops first-in-class precision medicines for cancer and other serious diseases, focusing on historically "undruggable" targets like transcription factors. As a spin-out from the oncology company Scorpion Therapeutics, Antares secured $177 million in Series A financing and aims to advance its small molecule programs into clinical trials starting in 2026.